StreetInsider.com News Articles

Form 6-K Quantum Biopharma Ltd. For: Jun 02

Tue, 02 Jun 2026 11:51:00 -0400

si-local-file:///var/storage/secattach/20260602/26589918.html

Form 6-K Quantum Biopharma Ltd. For: Jun 02

Tue, 02 Jun 2026 11:51:00 -0400

si-local-file:///var/storage/secattach/20260602/26589918.html

Quantum BioPharma hires IR Agency for investor relations services

Tue, 02 Jun 2026 07:40:43 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC, beginning June 8, 2026.

The six-month agreement will cost the biopharmaceutical company $250,000. Under the terms, the agency will create company profiles, distribute information to the financial community, build a digital community, market news distribution, and conduct lead generation campaigns.

IR Agency LLC operates independently from Quantum BioPharma. The agency and its principals do not hold equity interests in the company's securities or rights to acquire such interests. Rafael Pereira will lead the investor relations services for the company.

Quantum

Form 6-K Quantum Biopharma Ltd. For: Jun 02

Tue, 02 Jun 2026 07:40:00 -0400

si-local-file:///var/storage/secattach/20260602/26587529.html

Form 6-K Quantum Biopharma Ltd. For: Jun 02

Tue, 02 Jun 2026 07:40:00 -0400

si-local-file:///var/storage/secattach/20260602/26587529.html

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Tue, 02 Jun 2026 07:40:00 -0400

TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to announce that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC (the “Agency”) beginning on June 8, 2026.

Pursuant to the agreement, the Agency has agreed to communicate information about the Company, but not limited to, creating company profiles and media distribution to the financial community, building a digital community with respect to the Company,

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Tue, 02 Jun 2026 07:40:00 -0400

Form 6-K Quantum Biopharma Ltd. For: May 18

Mon, 18 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260518/26509674.html

Form 6-K Quantum Biopharma Ltd. For: May 18

Mon, 18 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260518/26509674.html

Quantum BioPharma reaches halfway point in imaging study with MGH

Mon, 18 May 2026 05:08:43 -0400

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that patient enrollment has reached the midpoint in its collaborative imaging study with Massachusetts General Hospital. The study aims to validate a positron emission tomography imaging technique for assessing demyelinated neurons in multiple sclerosis patients.

The research centers on the PET tracer [¹⁸F]3F4AP, developed by Pedro Brugarolas from MGH's Department of Radiology and Harvard Medical School. Early data from the first cohort shows signal detection in acute MS lesions and potential sensitivity to gray matter lesions using PET/MR and total-body PET platforms.

The imaging technique is designed to directly measure demyelinated lesions with intact axons and

Quantum BioPharma reaches halfway point in imaging study with MGH

Mon, 18 May 2026 05:08:43 -0400

The imaging technique is designed to directly measure demyelinated lesions with intact axons and

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital